Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 28,200 shares at $33.25 ($915K) on 2020-01-02, disclosed to the SEC on 2020-01-03.
Seasonal sale ($915k) by Chairman, President & CEO — this insider has traded ITCI in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.85 | 3,700 | $118K | 12.9% |
| 2 | $32.43 | 10,722 | $348K | 38.0% |
| 3 | $32.43 | 10,722 | $348K | 38.0% |
| 4 | $33.25 | 3,000 | $100K | 10.9% |
| 5 | $34.30 | 56 | $2K | 0.2% |
| Total | $32.44 avg | 28,200 |
| $915K |
| 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |